Journal article icon

Journal article

Phase I study of humanized monoclonal antibody AVE1642 directed against the type 1 insulin-like growth factor receptor (IGF-1R), administered in combination with anticancer therapies to patients with advanced solid tumors.

Abstract:

BACKGROUND: Type 1 insulin-like growth factor receptor (IGF-1R) mediates resistance to chemotherapy and targeted agents. This study assessed the safety, pharmacokinetics (PK), and tolerability of humanized IGF-1R antibody AVE1642 with other cancer treatments. PATIENTS: Patients with advanced solid tumors received three weekly AVE1642 dosed at 6 mg/kg, chosen following previous study, with 75 (cohort A) or 100 mg/m(2) (B) docetaxel, 1250 mg/m(2) gemcitabine/100 mg erlotinib (C1), or 60 mg/m(2)...

Expand abstract
Publication status:
Published

Actions


Access Document


Publisher copy:
10.1093/annonc/mds511

Authors


More by this author
Institution:
University of Oxford
Department:
Oxford, MSD, Oncology, Weatherall Insti. of Molecular Medicine
Role:
Author
More by this author
Institution:
University of Oxford
Department:
Oxford, MSD, Oncology
Role:
Author
Expand authors...
Journal:
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO
Volume:
24
Issue:
3
Pages:
784-791
Publication date:
2013-03-05
DOI:
EISSN:
1569-8041
ISSN:
0923-7534
URN:
uuid:7176a965-10ea-4d93-b112-54f1fc81405f
Source identifiers:
358467
Local pid:
pubs:358467

Terms of use


Metrics


Views and Downloads






If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP